Shares of Merck and Amgen are seeing declines Friday morning, dragging the Dow Jones Industrial Average into negative territory. The Dow was most recently trading 168 points, or 0.3%, lower, as shares ...
Zacks Investment Research on MSN
Amgen (AMGN) stock slides as market rises: Facts to know before you trade
In the latest trading session, Amgen (AMGN) closed at $344.55, marking a -1.17% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day. On the ...
1d
AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026.
Biotech giant Amgen on April 22 announced the retirement of David Reese, executive vice president and chief technology officer, who has been with the Thousand Oaks-based company for 21 years. Reese, ...
We recently compiled a list of the 10 Most Undervalued Dow Stocks to Buy Now. Amgen Inc. is one of the most undervalued ...
US biotech major Amgen has announced the retirement of David Reese, executive vice president and chief technology officer, ...
Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.
Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.
A former Amgen Inc. employee filed a proposed class action challenging the biotechnology company’s practice of charging ...
Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...
Amgen ( (AMGN)) has issued an update. On April 22, 2026, Amgen announced that David M. Reese, M.D., executive vice president and chief technology officer, will retire effective June 30, 2026, after a ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results